Xenon Pharmaceuticals (XENE) investor relations material

Executive summary

• NDA submission for azetukalner remains on track for Q3 2026 after a successful pre-NDA meeting with the FDA, with multiple Phase 3 studies advancing in epilepsy, MDD, and BPD and key topline data expected in H1 2027.

• No product sales to date; revenue derived from collaboration milestones, with $7.5M recognized in H1 2025 and none in H1 2026.

• Net loss increased to $213.0M for H1 2026, up from $149.8M in H1 2025, driven by higher R&D and G&A expenses.

• Cash, cash equivalents, and marketable securities totaled $1.25B as of June 30, 2026, providing a cash runway into 2029.

Financial highlights

• Cash, cash equivalents, and marketable securities increased to $1,245.1 million as of June 30, 2026, from $586.0 million at December 31, 2025.

• Research and development expenses rose to $187.7M in H1 2026 (up $51.5M year-over-year), mainly due to late-stage clinical trials and manufacturing for azetukalner.

• General and administrative expenses increased to $47.8M in H1 2026 (up $9.5M year-over-year), reflecting higher headcount and pre-commercialization activities.

• Net loss for Q2 2026 was $110.7 million, compared to $84.7 million in Q2 2025, reflecting higher R&D and G&A expenses, partially offset by increased interest income.

• Interest income grew to $19.1M in H1 2026, reflecting higher cash balances.

Outlook and guidance

• NDA submission for azetukalner in FOS is expected in Q3 2026; topline data for MDD anticipated in H1 2027.

• Cash runway projected to fund operations into 2029 based on current plans.

• Cash and investments expected to fund operations for at least the next 12 months.

• Anticipates continued operating losses as R&D and commercialization investments increase.